



SensoLyte[®] 520 FRET SIRT1 Assay Kit

Fluorimetric

Revision Number: 1.2

Last updated June 25, 2019

Catalog #	72155
Kit Size	100 Assays (96-well plate)

- **Optimized Performance:** This kit is optimized to detect SIRT1 activity.
- **Enhanced Value:** It provides ample reagents to perform 100 assays in a 96-well format.
- **High Speed:** The entire process can be completed in one hour
- **Assured Reliability:** Detailed protocol and references are provided.

Kit Components, Storage and Handling

Component	Description	Quantity
Component A	SIRT1 520 FRET substrate	1 mM, 50 μ L
Component B	Deacetylated FRET reference substrate, Ex/Em=490 nm/520 nm after cleavage	1 mM, 20 μ L
Component C	SIRT1, Human Recombinant	0.025 mg/mL, 400 μ L
Component D	Assay Buffer	20 mL
Component E	NAD ⁺	20 mM, 100 μ L
Component F	Nicotinamide (Sirtuin Inhibitor)	30 mM, 0.5 mL
Component G	SIRT1 Developer (10X)	0.5 mL

Other Materials Required (but not provided)

- Microplate: Black, flat-bottom 96-well plate.
- Fluorescence microplate reader: Capable of detecting emission at 520 nm with excitation at 490 nm.

Storage and Handling

- Store all kit components, except Component C, at -20°C.
- Store Component C at -80°C. Aliquot as needed to avoid freeze-thaw cycles.
- Protect Components A and B from light and from moisture.
- Component D can be stored at room temperature for convenience.

Introduction

Histone deacetylases (HDACs) act as transcriptional repressors of genes catalyzing the removal of acetyl groups from a ϵ -N-acetyl lysine of histone.¹ Sirtuins comprise a unique class of nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylases (class III HDACs) that target multiple protein substrates to execute diverse biological functions. Sirtuins catalyze a reaction that couples lysine deacetylation to NAD hydrolysis, yielding O-acetyl-ADP-ribose and nicotinamide.²

Sirtuin 1 (SIRT1), the human homolog of yeast Sir2 (Silent Information Regulator 2), is the most studied of the seven members of sirtuin family. SIRT1 have been implicated in several important cellular processes, including genomic stability and DNA repair,^{3,4} p53-mediated apoptosis,⁵ adipogenesis,⁶ and aging.^{7,8}

The SensoLyte[®] 520 FRET SIRT1 Assay Kit provides a homogeneous, two-step procedure for measuring sirtuin 1 activity. It contains a QXL[™] 520/5-FAM FRET substrate. The sequence is derived from a human FOXO3 sequence surrounding the deacetylation site of SIRT1.⁹ In the first step an acetylated substrate is incubated with sirtuin-containing samples. In the second step, deacetylated substrate is cleaved by the sirtuin developer, resulting in an increase of fluorescence that can be detected with excitation at 490 nm and emission at 520 nm. Fluorescence produced is proportional to SIRT1 activity. The kit is ideal for high throughput screening of SIRT1 inhibitors and activators. The long wavelength fluorescence of 5-FAM is less interfered by the autofluorescence of cell components and test compounds. Nuclear extract HDAC (containing HDACs 1 and 2) does not deacetylate FRET sirtuin substrate.

Protocol

Note 1: For standard curve, please refer to Appendix.

Note 2: Avoid protease inhibitors in the samples.

1. Prepare working solutions.

Note: Bring all kit components to room temperature before starting the experiment. Component C should be kept on ice after thawing.

1.1 SIRT1 FRET substrate solution: Dilute SIRT1 substrate (Component A) and NAD⁺ (Component E) in assay buffer (Component D). Both SIRT1 substrate and NAD⁺ should be diluted in assay buffer 100-fold. For each experiment, prepare fresh substrate solution.

Table 1. SIRT1 FRET substrate solution for one 96-well plate (100 assays)

Components	Volume
SIRT1 FRET substrate (100X, Component A)	50 μ L
NAD ⁺ (Component E)	50 μ L
Assay buffer (Component D)	4.9 mL
Total volume	5 mL

1.2 SIRT1, human recombinant enzyme (Component C): ready to use. For positive control, use 40 μL of Component C per well.

Note 1: The amount of SIRT1 (Component C) provided in this kit is enough to serve only as a positive control. More human recombinant SIRT1 may be ordered from AnaSpec (Cat#72212).

Note 2: Do not vortex the enzyme solution. Prolonged storage or vigorous agitation of the enzyme will cause denaturation. Store the enzyme solution on ice.

1.3 1X developer: Dilute the developer (Component G) and the nicotinamide (Component F) in assay buffer (Component D). Both developer and nicotinamide should be diluted 10-fold in assay buffer. Each well requires 50 μL of developer solution.

Table 2. 1X developer solution for one 96-well plate (100 assays)

Components	Volume
SIRT1 developer (10X, Component G)	500 μL
Nicotinamide (Component F)	500 μL
Assay buffer (Component D)	4 mL
Total volume	5 mL

Note 1: The developer, containing Nicotinamide, is a bi-functional buffer, which works as a stop solution for SIRT1 and initiates fluorescent signal releasing fluorophore.

Note 2: Prepare developer before use. Otherwise keep prepared solution on ice until use.

2. Set up the enzymatic reaction.

2.1 Add test compounds and SIRT1 enzyme to the microplate wells. For one assay in a 96-well plate, the suggested volume of enzyme solution is 40 μL and 10 μL of test compound.

2.2 Establish the following control wells at the same time, as deemed necessary:

- Positive control contains SIRT1 enzyme without test compound.
- Inhibitor/activator control contains SIRT1 enzyme and SIRT1 inhibitor/activator.
- Vehicle control contains SIRT1 enzyme and vehicle used in delivering test compound (e.g. DMSO, concentration not to exceed 1%).
- Test compound control contains assay buffer (Component D) and test compound. Some test compounds may themselves be fluorescent and thereby give false results.

Note: Test compound can be additionally tested for interference with fluorophore (see Appendix).

- Substrate control contains assay buffer (Component D).

2.3 Using the assay buffer (Component D), bring the total volume of all controls to 50 μL .

2.4 Pre-incubate the plate for 10 min at 37°C.

3. Detect SIRT1 activity.

- 3.1 Add 50 μL of the prepared SIRT1 substrate solution into each well, except the test compound control wells. Mix the reagents completely by shaking the plate gently for no more than 30 sec.
- 3.2 Incubate the plate for 30-60 minutes at 37°C.
- 3.3 Add 50 μL of the prepared developer solution and mix thoroughly.
- 3.4 Incubate the plate an additional 10 min at 37°C.
- 3.5 Measure fluorescence signal at Ex/Em=490 nm/520 nm.

3.6 Data analysis:

- The fluorescence reading from the substrate control well is used as the background fluorescence. This background reading should be subtracted from the readings of the other wells containing substrate. All fluorescence readings are expressed in relative fluorescence units (RFU).
- Plot data as RFU versus concentration of test compounds.
- A variety of data analyses can be done, e.g., determining inhibition %, EC_{50} , IC_{50} , etc.




Figure 1. Inhibition of SIRT1 by Ro-31-8220.

Appendix: Instrument Calibration

- Deacetylated reference substrate: Dilute 1 mM (Component B) to 10 μM in assay buffer (Component D). Do 2-fold serial dilutions to get concentrations of 5, 2.5, 1.25, 0.625, 0.313, and 0.156, include an assay buffer blank. Add 50 μL /well of these serially diluted deacetylated 520 reference solutions.
- Add 50 μL /well of the diluted SIRT1 substrate solution (refer to Protocol, step 1.1 for preparation).

Note: The addition of SIRT1 substrate solution to the reference standard is to correct for the absorptive quenching by the FRET peptide. If multiple concentrations of substrate are used, this step must be performed for each concentration.

- For proper comparison, add 50 μL /well of developer solution (refer to Protocol, Step 1.3 for preparation). Mix the reagents by shaking the plate gently for 3 to 5 sec.
- Incubate the plate for an additional 10 min at 37°C.
- Measure the fluorescence intensity of the reference substrate and substrate control wells at Ex/Em=490 nm/520 nm. Use the same setting of sensitivity as used in the enzyme reaction.
- Plot the deacetylated FRET fluorescent reference standard curve as RFU (relative fluorescent units) versus concentration as shown in Figure 2.

Note: The final concentrations of reference substrate are 5, 2.5, 1.25, 0.625, 0.313, 0.156, 0.078 and 0 μM . This reference standard is used to calibrate the variation of different instruments and different experiments. It is also an indicator of the amount of final product of the enzymatic reaction.

- If testing compounds for interference with developer solution, use deacetylated substrate at concentration that provides signal comparable to positive control. After incubation of deacetylated substrate with assay buffer or test compound, proceed with the addition of developer solution. This will allow discrimination between SIRT1 inhibition/activation versus interference with the developer.




Figure 2. Deacetylated FRET reference substrate. Deacetylated substrate was serially diluted with assay buffer containing acetylated FRET SIRT1 substrate, and after a 10 min incubation with developer, fluorescence was recorded at Ex/Em=490/520 nm (Flexstation 384II, Molecular Devices).

References:

1. Sterner, DE. et al. *Microbiol. Mol. Biol. Rev.* **64**, 435 (2000).
2. Longo, V and Kennedy, B. *Cell.* **126**, 257 (2006).
3. Yamagata, K and Kitabayashi, I. *Biochem Biophys Res Commun.* **390**, 1355 (2009).
4. Wang, RH. et al. *Cancer Cell.* **14**, 312 (2008).
5. Vaziri, H. et al. *Cell.* **107**, 149 (2001).
6. Picard, F. et al. *Nature.* **429**, 771 (2004).
7. Cohen, HY. et al. *Science* **305**, 390 (2004).
8. Trapp, J. and Jung, M. *Curr. Drug Target* **7**, 1553 (2006).
9. Taylor, DM. et al. *Cell. Mol. Life Sci.* **65**, 4000 (2008)